This observation is in line with ex vivo T cell stimulation experiments with tumor-infiltrating lymphocytes of epithelial ovarian cancer patients, where dual blockade of LAG-3 and PD-1 during priming of tumor antigen-specific T cells with tumor-derived APCs as weak stimulators increased T cell effector function to the levels observed with PB-derived APCs as stronger stimulators (32). The gene discussed is PDCD1; the disease is ovarian carcinoma.